Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
1. Novartis expects Kisqali to become a blockbuster drug. 2. Kisqali sales surged 64% globally, 100% in the U.S. 3. Entresto faces generic competition as patent expires next year. 4. Overall, Novartis' second-quarter sales rose 11% to $14.05 billion. 5. Company announces $10 billion share buyback, indicating growth confidence.